We’re hoping to see more early-stage funding in 2026 to help newer companies get off the ground. The public market, especially IPOs, has been a bit slow, with only 11 companies going public in 2025, ...
Vir Biotechnology, Inc. (VIR) has already been able to initiate its late-stage ECLIPSE program, which is using the combination of monoclonal antibody tobevibart in combination with small interfering ...
TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the European Patent Office and the Patent Office of the ...
For over a century, advances in science and technology have raised concerns spanning ethical, legal, safety, security, and environmental risks, often shaped by the type products, materials, knowledge, ...
SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has entered into an exclusive worldwide license agreement with Sanofi for three clinical-stage masked ...
HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological challenges. Opened in 2008, its ...
Of the nearly 400 million tons of plastic waste produced annually, about half ends up discarded, polluting landscapes and waterways worldwide. Developing sustainable ways to recover, break down and ...
– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results